New research from Spherix Global Insights reveals that despite advances in lupus treatment, including increased use of biologics and new therapies, many patients with systemic lupus erythematosus (SLE) continue to experience persistent symptoms, frequent flares, and reduced quality of life. Surveys of U.S. rheumatologists and lupus patients show that while doctors are adopting proactive strategies like earlier biologic use and treat-to-target approaches, fewer than half believe current treatments can achieve remission or low disease activity for most patients. Patients report ongoing disease burden and a need for better education on treatment options and management. The lupus treatment market is evolving with new drugs like Saphnelo® and anticipation for others like Gazyva®, but significant unmet needs remain for therapies that provide durable disease control and improve daily living.
The FTSE 100 fell 40 points to 10,639, with mixed sector performance as airlines and defence stocks gained while others like Primark owner AB Foods declined. Microsoft announced cutting 4,800 jobs to focus on growth priorities, causing a 1.7% drop in...
The FTSE 100 fell 26 points to 10,653 amid declines in major stocks like AstraZeneca and Rolls-Royce, while easyJet and ITV saw gains due to takeover and sale deals. UK banks anticipate eased capital requirements from the Bank of England, potentially...
Citi has maintained a 'buy' rating on AstraZeneca ahead of its Q2 earnings report due July 27, forecasting an 11% rise in earnings per share at constant exchange rates. The broker highlights upcoming phase three trial results for key drugs like Wainu...
The global AI in Pathology market, valued at $28.75 million in 2025, is projected to grow at a 9.12% CAGR to reach $68.81 million by 2035. Growth is driven by rising demand for digital pathology, AI diagnostics, and improved workflow efficiency throu...
